ArticleMolecular and cellular biology1997
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 268 citations in OpenAlex.
- Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.British journal of cancer · 2002Trial
- Review
- Cell Line-Specific Network Models of ERCancer research · 2021Article
- Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth.Molecules (Basel, Switzerland) · 2020Article
- Interplay Between KSHV and the Host DNA Damage Response.Frontiers in cellular and infection microbiology · 2020Review
- Regulation and New Treatment Strategies in Breast Cancer.Journal of life sciences (Westlake Village, Calif.) · 2019Article
- AFF3 upregulation mediates tamoxifen resistance in breast cancers.Journal of experimental & clinical cancer research : CR · 2018Article
- A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer.PloS one · 2018Article
- Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.BMC cancer · 2017Article
- The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance.Oncotarget · 2017Article
- Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells.Oncogenesis · 2017Article
- Cyclin D mediates tolerance of genome-doubling in cancers with functional p53.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.Frontiers in oncology · 2016Review
- Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.Cancer research · 2015Article
- Liganded ERα Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation.Molecular endocrinology (Baltimore, Md.) · 2015Article
- MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.Cellular and molecular life sciences : CMLS · 2014Article
- Polycomb protein SCML2 regulates the cell cycle by binding and modulating CDK/CYCLIN/p21 complexes.PLoS biology · 2013Article
- Cyclin-dependent kinase 4 may be expressed as multiple proteins and have functions that are independent of binding to CCND and RB and occur at the S and G 2/M phases of the cell cycle.Cell cycle (Georgetown, Tex.) · 2013Article
- The p53-estrogen receptor loop in cancer.Current molecular medicine · 2013Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to elucidate the mechanisms by which estrogens and antiestrogens modulate the growth of breast cancer cells, we have characterized the changes induced by estradiol that occur during the G1 phase of the cell cycle of MCF-7 human mammary carcinoma cells. Addition of estradiol relieves the cell cycle block created by tamoxifen treatment, leading to marked activation of cyclin E-cdk2 complexes and phosphorylation of the retinoblastoma protein within 6 h. Cyclin D1 levels increase significantly while the levels of cyclin E, cdk2, and the p21 and p27 cdk inhibitors are relatively constant. However, the p21 cdk inhibitor shifts from its association with cyclin E-cdk2 to cyclin D1-cdk4, providing an explanation for the observed activation of the cyclin E-cdk2 complexes. These results support the notion that cyclin D1 has an important role in steroid-dependent cell proliferation and that estrogen, by regulating the activities of G1 cyclin-dependent kinases, can control the proliferation of breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.